.
This guideline provides advice on the care of adults with advanced and progressive disease who require strong opioids for pain control, defined as those in severe pain who may be opioid-naïve, or those whose pain has been inadequately controlled by weak opioids such as codeine or tramadol (step 2 of the WHO pain ladder; Box 1).
The guideline does NOT cover:
 second-line treatment with strong opioids where a change in opioid treatment is required because of inadequate pain control or toxicity,  pain control during the last days of life,  palliative care in children.
Definitions of pain
Background pain is chronic, persistent pain. Breakthrough pain is a transient increase in pain intensity over background pain, typically of rapid onset and generally self-limiting with an average duration of 30 minutes.
Treatment and management

Strong opioids are:
 the main treatment for pain related to advanced and progressive disease.  represented at step 3 of the WHO pain ladder:
www.who.int/cancer/palliative/painladder/en (see Box 1) 
Counselling
When starting treatment with strong opioids discuss any concerns about:
 addiction,  tolerance,  adverse effects,  fears that treatment implies the final stages of life. Reassure patients that addiction is very rare and that tolerance does not significantly affect pain management or result in the need for escalating doses. Give verbal and written information to patients and carers on strong opioid treatment. Include the following:
 when and why strong opioids are used to treat pain,  how effective they are likely to be,  when and how often to take strong opioids and how long pain relief should last,  adverse effects and signs of toxicity,  safe storage. Give information on out of hours contact, follow-up and further prescribing. Offer access to frequent review.
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Management of adverse effects
Constipation
Constipation affects nearly all patients receiving strong opioid treatment. Prescribe regular laxative treatment at an effective dose to all patients who take strong opioids. Tell patients that treatment for constipation takes time to work and adherence is important.
Give laxative treatment at optimal doses before considering switching strong opioids.
Nausea
Transient nausea may occur when starting strong opioid treatment or when the dose is increased. If nausea persists, give optimal anti-emetic treatment before considering switching strong opioids. Transdermal patches -further information**
Drowsiness
Factors affecting absorption
Fever or external heat:  monitor patients using patches for increased adverse effects if they have a fever as increased absorption is possible,  avoid exposing application site to external heat, e.g. a hot bath or sauna as this may increase absorption.
Fentanyl transdermal patches** Are available as three day (72 hour) patches.
Buprenorphine transdermal patches** Are available as four day (96 hour) and seven day patches. Due to the long duration of action:  other opioids should not be administered within 24 hours of patch removal,  patients with severe adverse effects should be monitored for up to 30 hours after removing the patch.
Do NOT:
 offer fast-acting fentanyl as first-line rescue medication.  give transdermal patch formulations as first-line maintenance treatment if oral opioids are suitable.
